Professor Pontiano Kaleebu, the Director of Uganda Virus Research Institute-URVI/MRC and Chief Investigator in the PrEPVacc trial says, the testing which begun on Tuesday at the research site in Masaka is going to be done on a total 1,668 volunteers clustered in five groups ranging between 18 to 40 years of age, who have been drawn from HIV high risk communities in Uganda, Mozambique, Tanzania and South Africa.
More than one thousand volunteers have been enrolled to
participate in another version of the HIV vaccine trial conducted by Ugandan
scientists at the Medical Research Council-MRC.
The new HIV vaccine known as “PrEPVacc” is being tested for its efficacy in the
prevention of HIV, and at the same time, a second test is being done on a new
form of daily oral pre-exposure prophylaxis (PrEP) known as ,Descovy against
the existing standard for PrEP (Truvada).
Pontiano Kaleebu, the Director of Uganda Virus Research Institute-URVI/MRC and
Chief Investigator in the PrEPVacc trial says, the testing which began on
Tuesday at the research site in Masaka says that the
in five groups ranging between 18 to 40 years of age, from HIV high-risk
communities in Uganda, Mozambique, Tanzania and South Africa.
describes the trial as an African-led HIV vaccine efficacy trial which is directly
coordinated by Ugandan scientists, and one of its kind to be conducted outside
the United States of America.
Kareebu, says that they are going to run a two-ways prevention study that
will include administering of both oral PrEP and injectable vaccine within the
same trial, adding in the first phase of six months, the selected volunteers
are going to be monitored for their responses.
//Cue in; at the start….
out; ….risks of the study.”//
//Cue in: “okugezesa kuno….
Cue out; …..ejja kuba efunye.”//
He adds that such a significant HIV vaccine trial conducted in Uganda
presented to them great two opportunities which
their capacities in conducting big studies as well as earning them confidence
in the scientific research world.
also indicates that the PrEPVacc trial has made history as the first time UVRI
gets at a stage of testing HIV vaccine efficacy; the third phase in the process
of vaccines development and is it also the first of its kind in the whole of the
East African sub-region.
in; “very important…..
Cue out; ….part of history.”//
//Cue in: “kwegamba mu East Africa …
Cue out; ….okuwomamu omutwe.”//
Muzagira, the Director and Chief Investigator of the study explains that they
have been preparing for this efficacy trial since 2018.
they have also since completed several preparatory and early-phase studies in
which they have also prepared the communities for the process and meeting the
scientific regulatory requirements.
//Cue in: “starting a trial….
Cue out; ….do this research.”//
PrEPVacc trial, a scientific study funded by the European Union and Development
Countries Clinical Trials Partnership (EDCTP) will according to its design run-up
to March 2023, when it results are expected to be out.